HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company focused on transforming cardiac care by providing personalized insights and innovative solutions for ambulatory cardiac monitoring. The company offers the HeartBeam System, which is the first FDA-cleared cable-free, ambulatory 12-lead ECG device designed for use outside healthcare facilities. HeartBeam's products aim to enable the detection and monitoring of cardiac diseases such as Coronary Artery Disease (CAD) and Myocardial Infarction (MI).
- HeartBeam System - A cable-free synthesized 12-lead ECG capable of capturing the heart's electrical signals from three distinct directions, designed for portable devices to deliver actionable heart intelligence outside of a medical facility.
- 12-Lead ECG Synthesis Software - Converts the heart's electrical signals captured in 3 non-coplanar directions into a synthesized 12-lead ECG, with FDA 510(k) clearance for arrhythmia assessment.
- AI-Based Classification Algorithms - Designed to improve the detection of arrhythmias, including atrial flutter, with potential to outperform cardiologists in detecting some arrhythmias.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Robert Eno ExecutiveBoard | CEO | CEO of HeartBeam since October 17, 2024 , previously served as President since January 18, 2023. | View Report → | |
Branislav Vajdic Executive | President | Branislav Vajdic is the President and Founder of HeartBeam, Inc. since October 21, 2024, having previously served as CEO and board member starting September 10, 2021. | ||
Kenneth Persen Executive | Chief System Deployment Officer | Kenneth Persen is currently the Chief System Deployment Officer at BEAT, having joined the company on August 2, 2022 as its Chief Technology Officer. There is no additional information about board or other roles at BEAT. | ||
Timothy Cruickshank Executive | Chief Financial Officer | Timothy Cruickshank serves as the CFO at HeartBeam, Inc. since September 10, 2024, and previously served as CFO at ImpediMed from October 2019 to March 2024. |
- Given the FDA discussions remain "positive and productive" yet lack specific detail, can you clarify which performance metrics from the valid ECG study will critically drive the Q4 clearance decision?
- With the pilot commercialization set for Florida and Southern California, what specific criteria will you use to validate your pricing model and confirm market adoption within these geographically distinct regions?
- As you plan to hire a Chief Commercial Officer, how are you balancing the timing of this appointment against the need to optimize cash burn and manage dilution while scaling your commercial infrastructure?
- Considering the integration of the ACUCARDIa algorithm and upcoming wearable features, what contingency plans do you have if there are delays or technical issues that impact the overall ecosystem’s launch?
- In a market where players like iRhythm offer established diagnostic solutions, how will you differentiate your synthesized 12-lead ECG technology, and what measures are in place to secure sustainable long-term competitive advantage?
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
LIVMOR | 2023 | In February 2023, HeartBeam acquired LIVMOR’s Halo+ Atrial Fibrillation Detection System, the world’s first FDA‐cleared prescription wearable for continuous cardiac rhythm monitoring, along with intellectual property comprising three US patents, to extend its remote monitoring capabilities. |
Recent press releases and 8-K filings for BEAT.
- HeartBeam reported a net loss of $5.0 million for the second quarter of 2025, which was consistent with the net loss for the second quarter of 2024.
- As of June 30, 2025, the company's cash, cash equivalents, and short-term investments totaled $5.1 million. Net cash used in operating activities for the three months ended June 30, 2025, was $3.4 million, representing a 23% decrease quarter-over-quarter.
- The company continues productive discussions with the FDA regarding the 510(k) submission for its 12-lead ECG synthesis software, with clearance still anticipated by the end of the year.
- HeartBeam is actively executing on commercial readiness plans, with commercialization expected to begin upon receiving the 510(k) clearance for the 12-lead ECG synthesis software.
- Heartbeam Inc. has developed the first cable-free ECG capable of synthesizing a 12-lead ECG, having received foundational FDA clearance in December 2024 and anticipating a second clearance for the 12-lead synthesis algorithm by the end of 2025.
- The company plans to launch into the concierge medicine market by the end of 2025, estimating a serviceable market of up to $500 million in recurring revenue.
- Heartbeam reported a cash balance of $8.2 million as of March 31, 2025, and completed an $11.5 million common stock public offering in February 2025.
- The company expects margins to exceed 70% over time and believes it can reach breakeven with approximately 10% penetration in its initial target regions, or just over $20 million in revenue.
- Future opportunities include an expanded indication for heart attack detection, with potential FDA clearance in 2027, and an on-demand 12-lead patch.